Clinical Trial Update: A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC) [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating dostarlimab in combination with carboplatin and paclitaxel in Chinese participants with primary advanced or recurrent endometrial can…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Dostarlimab (dostarlimab)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Neoplasms, Endometrial | Phase 2 | Status: RECRUITING